Insulet Corp. (PODD)
137.80
+5.84
(+4.43%)
USD |
NASDAQ |
Sep 14, 16:00
137.83
+0.03
(+0.02%)
After-Hours: 20:00
Insulet Enterprise Value : 9.970B for Sept. 14, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 14, 2026 | 9.970B |
| September 11, 2026 | 9.565B |
| September 10, 2026 | 9.754B |
| September 09, 2026 | 9.978B |
| September 08, 2026 | 10.28B |
| September 04, 2026 | 10.64B |
| September 03, 2026 | 10.86B |
| September 02, 2026 | 10.69B |
| September 01, 2026 | 10.70B |
| August 31, 2026 | 10.72B |
| August 28, 2026 | 10.48B |
| August 27, 2026 | 10.36B |
| August 26, 2026 | 10.36B |
| August 25, 2026 | 10.33B |
| August 24, 2026 | 10.50B |
| August 21, 2026 | 10.69B |
| August 20, 2026 | 10.60B |
| August 19, 2026 | 10.92B |
| August 18, 2026 | 10.68B |
| August 17, 2026 | 10.10B |
| August 14, 2026 | 10.35B |
| August 13, 2026 | 10.57B |
| August 12, 2026 | 10.47B |
| August 11, 2026 | 10.45B |
| August 10, 2026 | 10.32B |
| Date | Value |
|---|---|
| August 07, 2026 | 10.20B |
| August 06, 2026 | 10.07B |
| August 05, 2026 | 9.655B |
| August 04, 2026 | 11.98B |
| August 03, 2026 | 12.18B |
| July 31, 2026 | 11.88B |
| July 30, 2026 | 11.90B |
| July 29, 2026 | 12.25B |
| July 28, 2026 | 12.03B |
| July 27, 2026 | 11.86B |
| July 24, 2026 | 11.74B |
| July 23, 2026 | 11.40B |
| July 22, 2026 | 11.44B |
| July 21, 2026 | 11.77B |
| July 20, 2026 | 12.02B |
| July 17, 2026 | 11.79B |
| July 16, 2026 | 11.82B |
| July 15, 2026 | 11.46B |
| July 14, 2026 | 11.45B |
| July 13, 2026 | 11.65B |
| July 10, 2026 | 11.60B |
| July 09, 2026 | 11.39B |
| July 08, 2026 | 11.33B |
| July 07, 2026 | 11.62B |
| July 06, 2026 | 11.49B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| DexCom, Inc. | 31.41B |
| Abbott Laboratories | 206.04B |
| Boston Scientific Corp. | 77.39B |
| PROCEPT BioRobotics Corp. | 1.053B |
| Globus Medical, Inc. | 9.689B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 95.00M |
| Revenue (Quarterly) | 801.70M |
| Total Expenses (Quarterly) | 706.70M |
| EPS Diluted (Quarterly) | 1.066 |
| Gross Profit Margin (Quarterly) | 72.56% |
| Profit Margin (Quarterly) | 11.85% |
| Earnings Yield | 3.66% |
| Operating Earnings Yield | 5.32% |
| Normalized Earnings Yield | 3.595 |